UPTRAVI® (selexipag) Selectively Targets the IP Receptor— The Key Target Within the Prostacyclin Pathway1,2

The IP receptor is the only established relaxant prostanoid receptor in the human pulmonary artery3

ESTABLISHED PROSTANOID RECEPTORS IN THE HUMAN PULMONARY ARTERY

Potential Causes of Vasoconstriction and Cell Proliferation

UPTRAVI selectively targets the IP receptor1

*Clinical significance in humans is unknown.